Bcl 2 fitc

Manufactured by BD

The Bcl-2 FITC is a lab equipment product that allows for the detection and quantification of Bcl-2 protein expression in cells. Bcl-2 is a key regulator of apoptosis, or programmed cell death. The FITC (fluorescein isothiocyanate) label enables visualization and analysis of Bcl-2 levels using flow cytometry or fluorescence microscopy techniques.

Automatically generated - may contain errors

Lab products found in correlation

Percp cy5, by BD (1 mentions) Hvem fc, by R&D Systems (1 mentions) Annexin 5, by Cell Signaling Technology (1 mentions) Cd8 apc cy7, by BioLegend (1 mentions) Cd16 apc cy7 3g8, by BioLegend (1 mentions) Ki67 pe cy7, by BD (1 mentions) Cd73 bv421, by BioLegend (1 mentions) Cd95 pe, by BD (1 mentions) Cx3cr1 percp cy5, by BioLegend (1 mentions) Live dead aqua, by Thermo Fisher Scientific (1 mentions) Live dead yellow, by Thermo Fisher Scientific (1 mentions) Cd3 bv605, by BD (1 mentions) Hla dr fitc, by BD (1 mentions) Cd38 apc, by BD (1 mentions) Cd69 pe cy7, by BD (1 mentions) Cd45ra apc, by BD (1 mentions)

Spelling variants of this product

Bcl-2 (78 citations) FITC-conjugated mouse anti-human Bcl-2 monoclonal antibody (2 citations)

2 protocols using bcl 2 fitc

Investigating TIL Activation and Apoptosis

Check if the same lab product or an alternative is used in the 5 most similar protocols

CD32⁺ or CD32⁺ HVEM⁺ L cells were harvested, pulsed with 200 ng/mL OKT3 and co-cultured at a 1:1 ratio with TIL. After 12 h, TIL were harvested and stained for CD8 and intracellular IκBα PerCP-Cy5.5 (BD). After 5 days, TIL were stained for CD8, 7-AAD, Annexin-V, Bcl-xL Alexa 488 (Cell Signaling), Bcl-2 FITC (BD), and Bcl-6 PerCP-Cy5.5 (BD). Additionally, sorted CD8⁺ BTLA⁺ and BTLA⁻ TILs were stimulated with 30 ng/mL plate-bound OKT3 and 10 μg/mL control human Ig, BTLA-Fc (R&D), or HVEM-Fc (R&D) with or without 10 μg/mL soluble anti-BTLA blocking mAb (clone 3B1) or PI3K inhibitor (10 nM GSK2126458). Cells were stained as described above.

Haymaker C.L., Wu R.C., Ritthipichai K., Bernatchez C., Forget M.A., Chen J.Q., Liu H., Wang E., Marincola F., Hwu P, & Radvanyi L.G. (2015). BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. Oncoimmunology, 4(8), e1014246.

+ Open protocol

+ Expand

Comprehensive Multiparametric Immunophenotyping of PBMCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

As part of the original A5314 study, cryopreserved PBMC specimens from A5314 (n=118) were thawed and stained with LiveDead Yellow (ThermoFisher), CD3-BV711 (clone UCHT1, BD), CD4-AlexaFluor(AF)-700 (RPA-T4, BD), CD8-BrilliantViolet(BV)-785 (RPA-T8, BD), HLA-DR-FITC (L243, BD), CD38-APC (HIT2, BD), CD14-Pacific Blue (M5E2, BD), CD16-APC-Cy7 (3G8, BioLegend), CX3CR1-PerCP-Cy5.5 (2A9-1, BioLegend), and CD69-PE-Cy7 (L78, BD). Additional aliquots of cryopreserved PBMCs from each donor at baseline and week 24 were then thawed and stained with a second panel, consisting of LiveDead Aqua (ThermoFisher), CD3-BV605 (SK7, BD), CD4-BrilliantUltraViolet(BUV)395 (SK3, BD), CD8-APC-Cy7 (SK1, BioLegend), CD45RA-APC (HI100, BD), CD27-BV786 (O323, BioLegend), CD95-PE (DX2, BD), CD127-PECF594 (A0195D5, BioLegend), CD39-PerCPCy5.5 (eBioA1, eBioscience), CD73-BV421 (AD2, BioLegend), Ki67-PECy7 (B56, BD), and Bcl-2-FITC (Bcl-2/100, BD). All researchers remained blinded to the treatment status of the donors during flow cytometry acquisition and gating.

Freeman M.L., Clagett B.M., Moisi D., Yeh E., Morris C.D., Ryu A., Rodriguez B., Stein J.H., Deeks S.G., Currier J.S., Hsue P.Y., Anthony D.D., Calabrese L.H., Ribaudo H.J, & Lederman M.M. (2022). Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV. Frontiers in Immunology, 13, 924718.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!